Drug Channels
JANUARY 22, 2025
As youll see below, the combination of formulary exclusion and private labels is creating an increasingly confusing and crowded biosimilar marketplace. For 2025, the Big Three PBMs shifted national formularies to favor their private-label biosimilars over Humira and its many biosimilar competitors. What do you think?
Drug Patent Watch
JANUARY 13, 2025
Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 billion by 2025, growing at a CAGR of 34.2%
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
NOVEMBER 16, 2023
While Europe has historically been a pioneer in the adoption of biosimilars, a new report by the global initiative Act4Biosimilars has revealed differences country by country, including disparities between Eastern and Western Europe. This is based on research from a report published in April this year by IQVIA.
Drug Channels
OCTOBER 18, 2022
The biosimilar boom for provider-administered drugs continues to accelerate. Net prices in therapeutic classes with biosimilar competition have declined by 60% or more over the past few years. Some major biological reference products have now lost a majority of their unit sales to their biosimilars. drug distribution.
Drug Channels
JULY 18, 2023
The Humira biosimilar market has arrived! This month, nine biosimilar versions of adalimumab launched in the U.S. Surprisingly, two PBMs—Express Scripts and OptumRx—will each offer at least one low-list-price biosimilar option on their main national formularies. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.
European Pharmaceutical Review
AUGUST 16, 2023
Sandoz has announced positive results from the MYLIGHT Phase III study for its biosimilar aflibercept, for patients living with wet macular degeneration. The confirmatory efficacy and safety study ( NCT04864834 ) demonstrated therapeutic equivalence between the biosimilar aflibercept and the reference biologic, Eylea®.
Drug Channels
SEPTEMBER 7, 2022
As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. In many therapeutic areas, biosimilars’ market share is approaching 80%. will face multiple biosimilar competitors. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Prices are dropping while adoption accelerates.
Expert insights. Personalized for you.
98 
Let's personalize your content